| EQS-Ad-hoc: BRAIN Biotech AG / Key word(s): Strategic Company Decision BRAIN Biotech AG terminates contract for natural sweetener solution with Roquette Frères 10-Feb-2023 / 11:04 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. BRAIN Biotech AG terminates contract for natural sweetener solution with Roquette Frères Zwingenberg, Germany February 10th, 2023 BRAIN Biotech AG (“BRAIN”) today announces the contract termination with Roquette Frères for the joint development of a natural sweetener solution. BRAIN is convinced of the project’s viability and economics of a natural sweetener alternative based on the molecule Brazzein. BRAIN owns the proprietary production technology for the molecule and will look to establish new partnerships on this program. Notifying person: Martina Schuster, Investor Relations BRAIN Biotech AG Darmstädter Str. 34-36, 64673 Zwingenberg, Germany www.brain-biotech.com Investor Relations Office Tel.: +49-(0)-6251-9331-0 Fax: +49-(0)-6251-9331-11 E-Mail: ir@brain-biotech.com
Information and Explanation of the Issuer to this announcement: About BRAIN Biotech BRAIN Biotech AG is a leading European industrial biotechnology specialist with a focus on nutrition, health and the environment. As a technology and solutions provider the company supports the biologization of industries with bio-based products and processes. From contract R&D with industrial partners to advancing own disruptive incubator projects and customized enzyme products, BRAIN’s broad cutting-edge biotech expertise and its agile teams are key to success. - BRAIN Biotech AG, Germany, is the parent company of the international BRAIN Group, distributing specialty B2B products like enzymes or bioactive natural products. The BRAIN Group has its own fermentation or production facilities in Continental Europe, UK and the US, which together with the associated biotechnological solution competency complete the value chain within the group. - As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption and to actively advance common societal goals. BRAIN Biotech´s products and services target at least five of the UN SDGs directly. - Since its IPO in 2016, BRAIN Biotech AG is listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394). 10-Feb-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com |
| Language: | English |
| Company: | BRAIN Biotech AG |
| Darmstädter Straße 34-36 | |
| 64673 Zwingenberg | |
| Germany | |
| Phone: | +49 (0) 62 51 / 9331-0 |
| Fax: | +49 (0) 62 51 / 9331-11 |
| E-mail: | ir@brain-biotech.com |
| Internet: | www.brain-biotech.com |
| ISIN: | DE0005203947 |
| WKN: | 520394 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1557251 |
| End of Announcement | EQS News Service |
| |
1557251 10-Feb-2023 CET/CEST
